Recursion, a biotech company founded in 2014 with the promise of developing 100 drugs in 10 years using AI in drug discovery, has faced significant challenges over the past decade. Despite its ambitious goals, the company has yet to bring a single drug to market, leading to a sharp decline in its stock value and financial performance.
In response to these difficulties, Recursion’s cofounder and CEO, Chris Gibson, decided to step down from his role last week. Taking his place as the new CEO is Najat Khan, who has served as the company’s head of R&D and chief commercial officer since April 2024. Khan brings a wealth of experience from her previous role at Johnson & Johnson, where she led a 250-person AI team and oversaw innovative medicine R&D strategy.
In a recent interview with Forbes, Khan expressed her determination to overcome the challenges facing Recursion and to leverage AI technology to bring new drugs to market. She acknowledged the skepticism surrounding the company’s ability to deliver on its promises but remained optimistic about its potential for success.
Khan highlighted Recursion’s internal pipeline, which includes promising drug candidates for cancer and rare diseases. She also mentioned milestone payments from pharmaceutical companies, such as a recent $30 million payment from Roche and Genentech, as indicators of progress.
Despite these positive developments, Khan acknowledged that there is still a long road ahead for AI-designed drugs to reach the market. Jefferies analyst Dennis Ding described Recursion’s drug discovery platform as “novel and promising,” but cautioned that validation may take time and clinical outcomes could be challenging to interpret.
As Recursion continues to decode biology and analyze massive amounts of data to drive drug discovery, Khan remains focused on translating the company’s innovative ideas into tangible results. With her leadership and expertise in AI and drug development, she aims to steer Recursion towards success in the competitive biotech industry.
Stay tuned for more updates on Recursion’s journey under Najat Khan’s leadership and the latest advancements in AI-driven drug discovery.
